Tiliroside is a new potential therapeutic drug for osteoporosis in mice

Kai Li, Yu Xiao, Ziyi Wang, Fangsheng Fu, Siyuan Shao, Fangming Song, Jinmin Zhao, Xixi Lin, Qian Liu, Jiake Xu

Research output: Contribution to journalArticle

Abstract

Osteoporosis is a class of metabolic bone disease caused by complexed ramifications. Overactivation of osteoclasts due to a sudden decreased estrogen level plays a pivotal role for postmenopausal women suffering from osteoporosis. Therefore, inhibiting osteoclast formation and function has become a major direction for the treatment of osteoporosis. Tiliroside (Tle) is a salutary dietary glycosidic flavonoid extracted from Oriental Paperbush flower, which has been reported to have an anti-inflammation effect. However, whether Tle affects the osteoclastogenesis and bone resorption remains unknown. Herein, we demonstrate that Tle prevents bone loss in ovariectomy in mice and inhibits osteoclast differentiation and bone resorption stimulated by receptor activator of nuclear factor-κB ligand (RANKL) in vitro. Molecular mechanism studies reveal that Tle reduces RANKL-induced activation of mitogen-activated protein kinase and T-cell nuclear factor 1 pathways, and osteoclastogenesis-related marker gene expression, including cathepsin K (Ctsk), matrix metalloproteinase 9, tartrate-resistant acid phosphatase (Acp5), and Atp6v0d2. Our research indicates that Tle suppresses osteoclastogenesis and bone loss by downregulating the RANKL-mediated signaling protein activation and expression. In addition, Tle inhibits intracellular reactive oxygen species generation which is related to the formation of osteoclasts. Therefore, Tle might serve as a potential drug for osteolytic disease such as osteoporosis.

Original languageEnglish
Pages (from-to)16263-16274
Number of pages12
JournalJournal of Cellular Physiology
Volume234
Issue number9
DOIs
Publication statusPublished - 1 Sep 2019

Fingerprint

Osteoporosis
Osteoclasts
Bone
Pharmaceutical Preparations
Osteogenesis
Bone Resorption
Therapeutics
T Cell Transcription Factor 1
Chemical activation
NFI Transcription Factors
Cathepsin K
Bone and Bones
T-cells
Metabolic Bone Diseases
Matrix Metalloproteinase 9
Ovariectomy
Cytoplasmic and Nuclear Receptors
Acid Phosphatase
tiliroside
Mitogen-Activated Protein Kinases

Cite this

Li, Kai ; Xiao, Yu ; Wang, Ziyi ; Fu, Fangsheng ; Shao, Siyuan ; Song, Fangming ; Zhao, Jinmin ; Lin, Xixi ; Liu, Qian ; Xu, Jiake. / Tiliroside is a new potential therapeutic drug for osteoporosis in mice. In: Journal of Cellular Physiology. 2019 ; Vol. 234, No. 9. pp. 16263-16274.
@article{6b77285a152c4d0eb50fdf908802e39a,
title = "Tiliroside is a new potential therapeutic drug for osteoporosis in mice",
abstract = "Osteoporosis is a class of metabolic bone disease caused by complexed ramifications. Overactivation of osteoclasts due to a sudden decreased estrogen level plays a pivotal role for postmenopausal women suffering from osteoporosis. Therefore, inhibiting osteoclast formation and function has become a major direction for the treatment of osteoporosis. Tiliroside (Tle) is a salutary dietary glycosidic flavonoid extracted from Oriental Paperbush flower, which has been reported to have an anti-inflammation effect. However, whether Tle affects the osteoclastogenesis and bone resorption remains unknown. Herein, we demonstrate that Tle prevents bone loss in ovariectomy in mice and inhibits osteoclast differentiation and bone resorption stimulated by receptor activator of nuclear factor-κB ligand (RANKL) in vitro. Molecular mechanism studies reveal that Tle reduces RANKL-induced activation of mitogen-activated protein kinase and T-cell nuclear factor 1 pathways, and osteoclastogenesis-related marker gene expression, including cathepsin K (Ctsk), matrix metalloproteinase 9, tartrate-resistant acid phosphatase (Acp5), and Atp6v0d2. Our research indicates that Tle suppresses osteoclastogenesis and bone loss by downregulating the RANKL-mediated signaling protein activation and expression. In addition, Tle inhibits intracellular reactive oxygen species generation which is related to the formation of osteoclasts. Therefore, Tle might serve as a potential drug for osteolytic disease such as osteoporosis.",
keywords = "MAPK, osteoclast differentiation, osteoporosis, tiliroside",
author = "Kai Li and Yu Xiao and Ziyi Wang and Fangsheng Fu and Siyuan Shao and Fangming Song and Jinmin Zhao and Xixi Lin and Qian Liu and Jiake Xu",
year = "2019",
month = "9",
day = "1",
doi = "10.1002/jcp.28289",
language = "English",
volume = "234",
pages = "16263--16274",
journal = "Journal Cellular Physiology",
issn = "0021-9541",
publisher = "John Wiley & Sons",
number = "9",

}

Li, K, Xiao, Y, Wang, Z, Fu, F, Shao, S, Song, F, Zhao, J, Lin, X, Liu, Q & Xu, J 2019, 'Tiliroside is a new potential therapeutic drug for osteoporosis in mice' Journal of Cellular Physiology, vol. 234, no. 9, pp. 16263-16274. https://doi.org/10.1002/jcp.28289

Tiliroside is a new potential therapeutic drug for osteoporosis in mice. / Li, Kai; Xiao, Yu; Wang, Ziyi; Fu, Fangsheng; Shao, Siyuan; Song, Fangming; Zhao, Jinmin; Lin, Xixi; Liu, Qian; Xu, Jiake.

In: Journal of Cellular Physiology, Vol. 234, No. 9, 01.09.2019, p. 16263-16274.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tiliroside is a new potential therapeutic drug for osteoporosis in mice

AU - Li, Kai

AU - Xiao, Yu

AU - Wang, Ziyi

AU - Fu, Fangsheng

AU - Shao, Siyuan

AU - Song, Fangming

AU - Zhao, Jinmin

AU - Lin, Xixi

AU - Liu, Qian

AU - Xu, Jiake

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Osteoporosis is a class of metabolic bone disease caused by complexed ramifications. Overactivation of osteoclasts due to a sudden decreased estrogen level plays a pivotal role for postmenopausal women suffering from osteoporosis. Therefore, inhibiting osteoclast formation and function has become a major direction for the treatment of osteoporosis. Tiliroside (Tle) is a salutary dietary glycosidic flavonoid extracted from Oriental Paperbush flower, which has been reported to have an anti-inflammation effect. However, whether Tle affects the osteoclastogenesis and bone resorption remains unknown. Herein, we demonstrate that Tle prevents bone loss in ovariectomy in mice and inhibits osteoclast differentiation and bone resorption stimulated by receptor activator of nuclear factor-κB ligand (RANKL) in vitro. Molecular mechanism studies reveal that Tle reduces RANKL-induced activation of mitogen-activated protein kinase and T-cell nuclear factor 1 pathways, and osteoclastogenesis-related marker gene expression, including cathepsin K (Ctsk), matrix metalloproteinase 9, tartrate-resistant acid phosphatase (Acp5), and Atp6v0d2. Our research indicates that Tle suppresses osteoclastogenesis and bone loss by downregulating the RANKL-mediated signaling protein activation and expression. In addition, Tle inhibits intracellular reactive oxygen species generation which is related to the formation of osteoclasts. Therefore, Tle might serve as a potential drug for osteolytic disease such as osteoporosis.

AB - Osteoporosis is a class of metabolic bone disease caused by complexed ramifications. Overactivation of osteoclasts due to a sudden decreased estrogen level plays a pivotal role for postmenopausal women suffering from osteoporosis. Therefore, inhibiting osteoclast formation and function has become a major direction for the treatment of osteoporosis. Tiliroside (Tle) is a salutary dietary glycosidic flavonoid extracted from Oriental Paperbush flower, which has been reported to have an anti-inflammation effect. However, whether Tle affects the osteoclastogenesis and bone resorption remains unknown. Herein, we demonstrate that Tle prevents bone loss in ovariectomy in mice and inhibits osteoclast differentiation and bone resorption stimulated by receptor activator of nuclear factor-κB ligand (RANKL) in vitro. Molecular mechanism studies reveal that Tle reduces RANKL-induced activation of mitogen-activated protein kinase and T-cell nuclear factor 1 pathways, and osteoclastogenesis-related marker gene expression, including cathepsin K (Ctsk), matrix metalloproteinase 9, tartrate-resistant acid phosphatase (Acp5), and Atp6v0d2. Our research indicates that Tle suppresses osteoclastogenesis and bone loss by downregulating the RANKL-mediated signaling protein activation and expression. In addition, Tle inhibits intracellular reactive oxygen species generation which is related to the formation of osteoclasts. Therefore, Tle might serve as a potential drug for osteolytic disease such as osteoporosis.

KW - MAPK

KW - osteoclast differentiation

KW - osteoporosis

KW - tiliroside

UR - http://www.scopus.com/inward/record.url?scp=85062339232&partnerID=8YFLogxK

U2 - 10.1002/jcp.28289

DO - 10.1002/jcp.28289

M3 - Article

VL - 234

SP - 16263

EP - 16274

JO - Journal Cellular Physiology

JF - Journal Cellular Physiology

SN - 0021-9541

IS - 9

ER -